ENDRA Life Sciences Inc. — Director's Dealing 2025

Oct 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2025-10-10

Reporting Person: DIGIANDOMENICO ANTHONY (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-10	Common Stock	A	70822	$7.06	Acquired	76265	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-10	Warrants	$6.81	A	141644	Acquired	2030-10-15	Common Stock (141644)	Direct

Footnotes

F1: The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F2: Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock.

F3: Includes unvested restricted stock units.